图卡替尼联合卡培他滨和曲妥珠单抗治疗HER2阳性转移性乳腺癌(含或不含脑转移):非随机、开放标签、1b期研究
这项在美国5个中心开展的非随机、开放标签1b期研究纳入60例既往接受过曲妥珠单抗、帕妥珠单抗和T-DM1治疗的HER2阳性进展期乳腺癌患者,确定图卡替尼推荐2期剂量为300 mg口服每日两次,与卡培他滨无药物相互作用,常见不良事件为腹泻、恶心、手足综合征等,未报告治疗相关死亡,联合方案显示初步抗肿瘤活性。
要点
- 图卡替尼推荐2期剂量为300 mg口服每日两次。
- 图卡替尼与卡培他滨无药物相互作用。
- 联合方案常见不良事件包括腹泻、恶心、手足综合征。
核心结论
- 图卡替尼联合卡培他滨和曲妥珠单抗毒性可接受并显示初步抗肿瘤活性。
- 研究结果将在双盲随机研究HER2CLIMB中验证。
研究设计与样本
- 非随机、开放标签1b期研究,在美国5个中心开展。
- 招募18岁及以上HER2阳性进展期乳腺癌患者,既往接受过曲妥珠单抗、帕珠单抗和T-DM1治疗。
- 采用改良3+3剂量递增设计确定推荐2期剂量。
- 主要终点为最大耐受剂量和推荐2期剂量,通过毒性评估。
主要发现
- 图卡替尼推荐2期剂量为300 mg口服每日两次,等同于单药最大耐受剂量。
- 药代动力学分析显示与卡培他滨无药物相互作用。
- 推荐2期剂量下常见不良事件(不考虑因果关系、分级和治疗组):腹泻35/52例(67%)、恶心31/52例(60%)、手足综合征23/52例(44%)、疲乏20/52例(38%)、呕吐20/52例(38%)。
- 所有患者中治疗相关3级及以上毒性包括疲乏5例(8%)、腹泻4例(7%)、手足综合征4例(7%),未报告治疗相关死亡。
关键数值与推荐
- 图卡替尼推荐2期剂量:300 mg口服每日两次。
- 卡培他滨剂量:1000 mg/m2口服每日两次,每21天周期用14天。
- 曲妥珠单抗剂量:6 mg/kg静脉注射每21天一次。
临床怎么用
- 对于既往多线治疗的HER2阳性转移性乳腺癌患者,图卡替尼联合卡培他滨和曲妥珠单抗方案毒性可接受且显示初步疗效。
- 需关注腹泻、手足综合征等不良事件的管理。
局限性
- 非随机、开放标签设计,样本量小。
- 研究为1b期,疗效为初步结果,需随机研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on currently available therapies. We aimed to determine the recommended phase 2 dose, safety, pharmacokinetics, and preliminary activity of tucatinib in combination with capecitabine or trastuzumab in patients with HER2-positive breast cancer with or without brain metastases. METHODS: In this non-randomised, open-label, phase 1b trial done in five sites in the USA, we recruited patients aged 18 years or older with HER2-positive progressive breast cancer who had been previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine. Eligible patients required HER2-positivity assessed locally, evaluable lesions as defined per Response Evaluation Criteria in Solid Tumors, version 1.1, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Tucatinib was administered twice a day in conjunction with capecitabine 1000 mg/m2 orally twice a day for 14 days of a 21-day cycle, trastuzumab 6 mg/kg intravenously once every 21 days, or both. A modified 3 + 3 dose-escalation design was used to determine the recommended phase 2 dose, starting with tucatinib in combination with capecitabine or trastuzumab, and subsequently evaluating the triplet combination. The primary endpoint was to establish the maximum tolerated dose and recommended phase 2 dose of tucatinib, evaluated by toxicity assessments. Efficacy was assessed in all patients by contrast CT of the body. Analyses included all patients who had received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, number NCT02025192. FINDINGS: Between Jan 15, 2014, and Dec 15, 2015, 60 patients were enrolled and treated. The current report is from mature data as of June 30, 2017. The tucatinib recommended phase 2 dose was determined to be 300 mg orally twice a day, equivalent to single-agent maximum tolerated dose. Pharmacokinetic analysis showed that there was no drug-drug interaction with capecitabine. Adverse events seen at the recommended phase 2 dose regardless of causality, grade, and treatment group included diarrhoea (35 [67%] of 52 patients), nausea (31 [60%] patients), palmar-plantar erythrodysaesthesia syndrome (23 [44%] patients), fatigue (20 [38%] patients), and vomiting (20 [38%] patients). In all patients, treatment-related toxicities of grade 3 and worse included fatigue (five [8%] patients), diarrhoea (four [7%] patients), and palmar-plantar erythrodysaesthesia (four [7%] patients). No treatment-related deaths were reported. The proportion of patients with measurable disease achieving objective response was 83% (five of six patients) in the combination of tucatinib with capecitabine, 40% (six of 15 patients) in the combination of tucatinib with trastuzumab, and 61% (14 of 23 patients) in the combination of tucatinib with both capecitabine and trastuzumab. INTERPRETATION: Tucatinib in combination with capecitabine and trastuzumab had acceptable toxicity and showed preliminary anti-tumour activity. Validation of the current study results will be determined in the double-blinded randomised study, HER2CLIMB (ONT-380-206; NCT02614794). FUNDING: Cascadian Therapeutics, a wholly owned subsidiary of Seattle Genetics.
引用
- Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018. PMID: 29804905. doi:10.1016/S1470-2045(18)30256-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。